Effects of HMGB2 silencing on proliferation, apoptosis, invasion and migration of breast cancer cell line MDA?MB?231

LIU Aihui; LI Xiunan; WANG Gangyue; TANG Xin; DONG Yi; JI Nan; KANG Hua

doi:10.3969/j.issn.1009-0460.2017.01.001

Abstract：Objective To investigate the effect of HMGB2 silencing on proliferation, apoptosis, invasion and migration of breast cancer cell line MDA?MB?231. Methods The lentiviral vector was constructed by cloning the oligonucleotides targeting HMGB2 into pLKO.1 puro vector. MDA?MB?231 cells were divided into control group, empty transfection group and HMGB2 interference group. The empty transfection group was transfected with random sequence shRNA and HMGB2 interference group was transfected with lentivi?ral vector targeting HMGB2 shRNA. The control group was treated with routine culture without any transfection. Western blotting was used to detect the level of HMGB2 protein after transfection for 48 h in each group to evaluate the efficiency of transfection. MTT meth?od was used to calculate the survival rate of each group. Flow cytometry was used to detect the apoptosis rate after transfection for 48 h. The Transwell method was used to detect the invasion and metastasis of 48 h after transfection. Results The level of HMGB2 protein in the HMGB2 interference group was lower than those in control group and empty transfection group, and the difference was statistical?ly significant ( P<005) . Compared with control group and empty transfection group, the survival rate of HMGB2 interference group was decreased, and there was a decreasing trend with the increase of transfection time ( P<005) . The early, late and total apoptosis rates of HMGB2 interference group were higher than those in the other two groups, and the number of invasive cells and the number of migrating cells were lower than the other two groups ( P<005) . Conclusion Silencing HMGB2 expression via shRNA in MDA?MB?231 cells has a significant effect, can inhibit cell proliferation, invasion, migration and induce cell apoptosis, to provide a reference for breast cancer targeted therapy.